How come that biosimilar medicines are still heavily debated today?

Access to medicines and security of supply should be central… 13 June 2023 Generic and biosimilar medicines significantly lower healthcare treatment costs and…
Smart reform of EU pharma and IP legislation key to boosting… 28 June 2022 Generic and biosimilar medicines lower healthcare treatment costs dramatically and…
EMA/HMA share definitive EU-wide position on biosimilar… 19 September 2022 The Biosimilar medicines group, a Medicines for Europe sector group,…
Common Statement: Supporting Statement for the Council… 14 June 2023 As trade associations representing off-patent medicines and Active Pharmaceutical Ingredients…